Skip to main content
Erschienen in: Journal of Neural Transmission 4/2013

01.04.2013 | Neurology and Preclinical Neurological Studies - Review Article

Instruments for holistic assessment of Parkinson’s disease

verfasst von: Pablo Martinez-Martin

Erschienen in: Journal of Neural Transmission | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Assessment of Parkinson’s disease is a complex matter as a consequence of the variety of manifestations and complications that can be present in a patient. Although a really holistic assessment is probably a utopia, a comprehensive evaluation is possible using a combination of measures completed by health professionals, patients and/or caregivers. In PD, main domains requiring assessment include motor impairment, motor complications, non-motor symptoms, disability, and patient-reported outcomes. Such scales like the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale and the battery of Scales for Outcomes in Parkinson’s disease (SCOPA) provide a wide information on the most relevant aspects of the disease. Hoehn and Yahr staging, global impression, and quality of life measures furnish summarized whole evaluations and comprehensive non-motor symptom assessments help to identify and evaluate this kind of manifestations. This article shows a pragmatic review of common instruments (rating scales and questionnaires) usable for a comprehensive assessment of PD and provides information about sources for guiding the selection of measures and outcome analyses.
Literatur
Zurück zum Zitat Antonini A, Abbruzzese G, Ferini-Strambi L et al (2012) Validation of the Italian version of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale. Neurol Sci. doi:10.1007/s10072-012-1112-z Antonini A, Abbruzzese G, Ferini-Strambi L et al (2012) Validation of the Italian version of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale. Neurol Sci. doi:10.​1007/​s10072-012-1112-z
Zurück zum Zitat Bech P (1993) Rating scales for psychopathology, health status, and quality of life. Springer, Berlin, pp 33–35CrossRef Bech P (1993) Rating scales for psychopathology, health status, and quality of life. Springer, Berlin, pp 33–35CrossRef
Zurück zum Zitat Bowling A (2005) Measuring health. A review of quality of life measurement scales. Open University Press, Berkshire Bowling A (2005) Measuring health. A review of quality of life measurement scales. Open University Press, Berkshire
Zurück zum Zitat Chaudhuri KR, Martinez-Martin P, Schapira AH et al (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 21:916–923PubMedCrossRef Chaudhuri KR, Martinez-Martin P, Schapira AH et al (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 21:916–923PubMedCrossRef
Zurück zum Zitat Chaudhuri KR, Martinez-Martin P, Brown RG et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22:1901–1911PubMedCrossRef Chaudhuri KR, Martinez-Martin P, Brown RG et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22:1901–1911PubMedCrossRef
Zurück zum Zitat Evatt ML, Chaudhuri KR, Chou KL et al (2009) Dysautonomia rating scales in Parkinson’s disease: sialorrhea, dysphagia, and constipation—critique and recommendations by Movement Disorders Task Force on rating scales for Parkinson’s disease. Mov Disord 24:635–646PubMedCrossRef Evatt ML, Chaudhuri KR, Chou KL et al (2009) Dysautonomia rating scales in Parkinson’s disease: sialorrhea, dysphagia, and constipation—critique and recommendations by Movement Disorders Task Force on rating scales for Parkinson’s disease. Mov Disord 24:635–646PubMedCrossRef
Zurück zum Zitat Fahn S, Elton RL, Members of the UPDRS Development Committee (1987) Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease, vol 2. Macmillan Healthcare Information, Florham Park, pp 153–164 Fahn S, Elton RL, Members of the UPDRS Development Committee (1987) Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease, vol 2. Macmillan Healthcare Information, Florham Park, pp 153–164
Zurück zum Zitat Friedberg G, Zoldan J, Weizman A, Melamed E (1998) Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson’s disease. Clin Neuropharmacol 21:280–284PubMed Friedberg G, Zoldan J, Weizman A, Melamed E (1998) Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson’s disease. Clin Neuropharmacol 21:280–284PubMed
Zurück zum Zitat Gallagher DA, Goetz CG, Stebbins G et al (2012) Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson’s disease. Mov Disord 27:79–83PubMedCrossRef Gallagher DA, Goetz CG, Stebbins G et al (2012) Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson’s disease. Mov Disord 27:79–83PubMedCrossRef
Zurück zum Zitat Goetz CG, Poewe W, Rascol O et al (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19:1020–1028PubMedCrossRef Goetz CG, Poewe W, Rascol O et al (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19:1020–1028PubMedCrossRef
Zurück zum Zitat Goetz CG, Fahn S, Martinez-Martin P et al (2007) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format and clinimetric testing plan. Mov Disord 22:41–47PubMedCrossRef Goetz CG, Fahn S, Martinez-Martin P et al (2007) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format and clinimetric testing plan. Mov Disord 22:41–47PubMedCrossRef
Zurück zum Zitat Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129–2170PubMedCrossRef Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129–2170PubMedCrossRef
Zurück zum Zitat Guy W (1976). Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology. Revised. NIMH publication DHEW publ NO (Adm) 76-338. National Institute of Mental Health, Bethesda, pp 217–222 Guy W (1976). Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology. Revised. NIMH publication DHEW publ NO (Adm) 76-338. National Institute of Mental Health, Bethesda, pp 217–222
Zurück zum Zitat Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17:427–442PubMedCrossRef Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression, and mortality. Neurology 17:427–442PubMedCrossRef
Zurück zum Zitat Jenkinson C, Fitzpatrick R, Peto V et al (1997a) The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 26:353–357PubMedCrossRef Jenkinson C, Fitzpatrick R, Peto V et al (1997a) The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing 26:353–357PubMedCrossRef
Zurück zum Zitat Jenkinson C, Fitzpatrick R, Peto V (1997b) The PDQ-8: development and validation of a short-form Parkinson’s Disease Questionnaire. Psychol Health 12:805–814CrossRef Jenkinson C, Fitzpatrick R, Peto V (1997b) The PDQ-8: development and validation of a short-form Parkinson’s Disease Questionnaire. Psychol Health 12:805–814CrossRef
Zurück zum Zitat Marinus J, Visser M, Martinez-Martin P et al (2003a) A short psychosocial questionnaire for patients with Parkinson’s disease: the SCOPA-PS. J Clin Epidemiol 56:61–67PubMedCrossRef Marinus J, Visser M, Martinez-Martin P et al (2003a) A short psychosocial questionnaire for patients with Parkinson’s disease: the SCOPA-PS. J Clin Epidemiol 56:61–67PubMedCrossRef
Zurück zum Zitat Marinus J, Visser M, van Hilten JJ et al (2003b) Assessment of sleep and sleepiness in Parkinson disease. Sleep 26:1049–1054PubMed Marinus J, Visser M, van Hilten JJ et al (2003b) Assessment of sleep and sleepiness in Parkinson disease. Sleep 26:1049–1054PubMed
Zurück zum Zitat Marinus J, Visser M, Verwey NA et al (2003c) Assessment of cognition in Parkinson’s disease. Neurology 61:1222–1228PubMedCrossRef Marinus J, Visser M, Verwey NA et al (2003c) Assessment of cognition in Parkinson’s disease. Neurology 61:1222–1228PubMedCrossRef
Zurück zum Zitat Marinus J, Visser M, Stiggelbout AM et al (2004) A short scale for the assessment of motor impairments and disabilities in Parkinson’s disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatry 75:388–395PubMedCrossRef Marinus J, Visser M, Stiggelbout AM et al (2004) A short scale for the assessment of motor impairments and disabilities in Parkinson’s disease: the SPES/SCOPA. J Neurol Neurosurg Psychiatry 75:388–395PubMedCrossRef
Zurück zum Zitat Martinez-Martin P, Kurtis MM (2012) Health-related quality of life as an outcome variable in Parkinson’s disease. Ther Adv Neurol Disord 5:105–117PubMedCrossRef Martinez-Martin P, Kurtis MM (2012) Health-related quality of life as an outcome variable in Parkinson’s disease. Ther Adv Neurol Disord 5:105–117PubMedCrossRef
Zurück zum Zitat Martinez-Martin P, Forjaz MJ, Cubo E, Frades B (2006) Global versus factor-related impression of severity in Parkinson’s disease: a new clinimetric index (CISI-PD). Mov Disord 21:208–214PubMedCrossRef Martinez-Martin P, Forjaz MJ, Cubo E, Frades B (2006) Global versus factor-related impression of severity in Parkinson’s disease: a new clinimetric index (CISI-PD). Mov Disord 21:208–214PubMedCrossRef
Zurück zum Zitat Martinez-Martin P, Schapira AH, Stocchi F et al (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting: study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22:1623–1629PubMedCrossRef Martinez-Martin P, Schapira AH, Stocchi F et al (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting: study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22:1623–1629PubMedCrossRef
Zurück zum Zitat Martinez-Martin P, Rodriguez-Blazquez C, Abe K et al (2009a) International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease. Neurology 73:1584–1591PubMedCrossRef Martinez-Martin P, Rodriguez-Blazquez C, Abe K et al (2009a) International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease. Neurology 73:1584–1591PubMedCrossRef
Zurück zum Zitat Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ et al (2009b) The clinical impression of Severity Index for Parkinson’s disease: international validation study. Mov Disord 24:211–217PubMedCrossRef Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ et al (2009b) The clinical impression of Severity Index for Parkinson’s disease: international validation study. Mov Disord 24:211–217PubMedCrossRef
Zurück zum Zitat Martinez-Martin P, Jeukens-Visser M, Lyons KE et al (2011) Health-related Quality of Life Scales in Parkinson’s Disease: critique and recommendations. Mov Disord 26:2371–2380PubMedCrossRef Martinez-Martin P, Jeukens-Visser M, Lyons KE et al (2011) Health-related Quality of Life Scales in Parkinson’s Disease: critique and recommendations. Mov Disord 26:2371–2380PubMedCrossRef
Zurück zum Zitat Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M et al (2013) Expanded and independent validation of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). J Neurol 260:228–236PubMedCrossRef Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M et al (2013) Expanded and independent validation of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). J Neurol 260:228–236PubMedCrossRef
Zurück zum Zitat Mokkink LB, Terwee CB, Knol DL et al (2010) The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol 10:22PubMedCrossRef Mokkink LB, Terwee CB, Knol DL et al (2010) The COSMIN checklist for evaluating the methodological quality of studies on measurement properties: a clarification of its content. BMC Med Res Methodol 10:22PubMedCrossRef
Zurück zum Zitat Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease (2003) The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 18:738–750CrossRef Movement Disorder Society Task Force on Rating Scales for Parkinson’s Disease (2003) The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 18:738–750CrossRef
Zurück zum Zitat Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 4(3):241–248PubMedCrossRef Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 4(3):241–248PubMedCrossRef
Zurück zum Zitat Rabey JM, Baas H, Bonuccelli U et al (1997) Evaluation of the Short Parkinson’s Evaluation Scale: a new friendly scale for the evaluation of Parkinson’s disease in clinical drug trials. Clin Neuropharmacol 20:322–337PubMedCrossRef Rabey JM, Baas H, Bonuccelli U et al (1997) Evaluation of the Short Parkinson’s Evaluation Scale: a new friendly scale for the evaluation of Parkinson’s disease in clinical drug trials. Clin Neuropharmacol 20:322–337PubMedCrossRef
Zurück zum Zitat Sherbourne CD, Sturm R, Wells KB (1999) What outcomes matter to patients? J Gen Intern Med 14:357–363PubMedCrossRef Sherbourne CD, Sturm R, Wells KB (1999) What outcomes matter to patients? J Gen Intern Med 14:357–363PubMedCrossRef
Zurück zum Zitat The EuroQol Group (1990) EuroQol—a new facility for the measurement of health related quality of life. Health Policy 16:199–208CrossRef The EuroQol Group (1990) EuroQol—a new facility for the measurement of health related quality of life. Health Policy 16:199–208CrossRef
Zurück zum Zitat Visser M, Marinus J, Stiggelbout AM, van Hilten JJ (2004) Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov Disord 19:1306–1312 Visser M, Marinus J, Stiggelbout AM, van Hilten JJ (2004) Assessment of autonomic dysfunction in Parkinson’s disease: the SCOPA-AUT. Mov Disord 19:1306–1312
Zurück zum Zitat Visser M, Verbaan D, van Rooden SM et al (2007) Assessment of psychiatric complications in Parkinson’s disease: the SCOPA-PC. Mov Disord 22:2221–2228PubMedCrossRef Visser M, Verbaan D, van Rooden SM et al (2007) Assessment of psychiatric complications in Parkinson’s disease: the SCOPA-PC. Mov Disord 22:2221–2228PubMedCrossRef
Zurück zum Zitat Wyrwich KW, Norquist JM, Lenderking WR et al (2012) Methods for interpreting change over time in patient-reported outcome measures. Qual Life Res. doi:10.1007/s11136-012-0175-x Wyrwich KW, Norquist JM, Lenderking WR et al (2012) Methods for interpreting change over time in patient-reported outcome measures. Qual Life Res. doi:10.​1007/​s11136-012-0175-x
Metadaten
Titel
Instruments for holistic assessment of Parkinson’s disease
verfasst von
Pablo Martinez-Martin
Publikationsdatum
01.04.2013
Verlag
Springer Vienna
Erschienen in
Journal of Neural Transmission / Ausgabe 4/2013
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-013-1005-1

Weitere Artikel der Ausgabe 4/2013

Journal of Neural Transmission 4/2013 Zur Ausgabe

Neurology and Preclinical Neurological Studies - Review Article

Centenary of Lewy bodies (1912–2012)

Neurology and Preclinical Neurological Studies - Review Article

Musculoskeletal problems in Parkinson’s disease

Neurology and Preclinical Neurological Studies - Review Article

The pharmacology of Tourette syndrome

Neurology and Preclinical Neurological Studies - Original Article

In vivo neurochemical imaging of olfactory dysfunction in Parkinson’s disease

Neurology and Preclinical Neurological Studies - Short Communication

The impact of deep brain stimulation on the nonmotor symptoms of Parkinson’s disease

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Vierten reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.